the active ind and available development programs (13of14) redi 2018
Published 4 years ago • 2.5K plays • Length 53:38Download video MP4
Download video MP3
Similar videos
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
33:18
investigational new drug (ind) submission: content/format and first 30 days (5of14) redi 2018
-
41:00
fda regulatory requirements for clinical investigators and case examples (9of14) redi 2018
-
40:34
demystifying the investigational new drug (ind) application for drugs and biologics (3of14) redi '18
-
15:46
office of regulatory affairs update (1of14) redi 2018
-
18:10
sbia program overview - redi 2020
-
32:21
good manufacturing practices (gmps) from an ind perspective (11of14) redi 2018
-
36:51
investigational new drug safety reporting requirements (10of14) redi 2018
-
44:32
walkthrough of a pre-approval manufacturing site inspection (14of14) redi 2018
-
5:03
introduction to the fda office of training, education, and development’s train-the-trainer program
-
5:37
gdufa ii training - pre anda product development meetings, robert lionberger
-
20:56
pre-anda program overview (2of39) complex generics 2018
-
14:06
establishing appropriate be limits for complex formulations (14of39) complex generics 2018
-
18:22
electronic submissions (7of27) generic drugs forum 2018
-
11:32
determining whether to submit an anda or a 505(b)(2) application (12of27) generic drugs forum 2018
-
57:22
fda webinar on new infant formula transition plan (part 2)
-
1:00:11
human factors engineering in medical products reviews (2of14) redi 2018
-
35:38
safety reporting requirements and safety assessment for ind and ba/be studies
-
40:24
fda communication during drug development (4/14) redi 2017